Aduro biotech, inc. (ADRO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash Flows from Operating Activities
Net loss

-7,575

-19,415

-20,952

-18,578

-23,427

-26,320

-23,147

-24,396

-21,494

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-21,812

-

-35,051

2,296

-28,827

3,100

567

-26,260

-16,616

-920

-4,684

-3,626

-7,784

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

1,000

-

-

-

1,100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

1,100

1,078

-

888

833

826

773

491

382

357

253

162

126

93

78

68

51

43

Amortization of intangible assets

100

137

138

179

100

141

144

147

152

146

145

136

132

134

138

140

137

89

0

0

0

-

-

-

-

Impairment of property and equipment

1,199

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash lease expense

380

283

228

217

219

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discounts and amortization of premiums on marketable securities

294

299

515

503

353

267

281

306

213

-77

-47

-154

-343

-369

-417

-495

-550

-

-

-

-

-

-

-

-

Stock-based compensation

2,035

2,325

3,075

3,336

3,703

4,002

4,221

4,327

4,924

4,366

4,025

3,997

3,988

4,154

3,784

3,325

3,743

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,765

580

-

164

95

109

Excess tax benefit from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-477

2,736

24

2,161

-

-

-

-

-

-

-

-

Loss from remeasurement of fair value of contingent consideration

944

-

-

-

-

65

210

-5

365

-

-

-

-

713

4

0

-317

-

-

-

-

-

-

-

-

Loss from remeasurement of fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

16,735

9,342

284

157

-221

346

Non-cash interest expense related to convertible promissory notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

32

996

1,354

Loss on disposal of property and equipment

-

-

-

-

-

-24

0

1

-4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax

-

-130

-2,250

-35

-35

-47

-40

-38

-21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

711

120

-1,141

656

-11,330

12,037

-1,041

340

-288

-359

-2,028

3,612

-1,374

82

-328

-483

-2,979

1,699

2,086

530

-2,622

3,029

11

93

-337

Income tax receivable

5,665

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-1,277

145

-59

-980

368

625

-91

-1,275

-265

133

-7,500

3,394

2,438

-6,426

-6,135

3,053

6,021

199

493

1,186

776

649

456

-567

579

Accounts payable

702

-1,208

758

-551

202

559

643

-1,348

679

-343

-1,470

249

358

495

-532

-2,954

140

-672

1,316

-125

1,018

1,083

-2,035

2,414

219

Deferred revenue

-2,897

-3,290

-4,705

-3,589

-3,174

9,534

-3,062

-2,540

-3,644

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-3,773

-

-3,711

-3,781

-3,761

-8,131

183,459

-9,192

-9,072

-

-

-

-

Accrued clinical trial and manufacturing expenses

218

247

124

1,143

216

-1,224

-336

335

-2,075

-657

2,157

-587

11

-2,506

-6,595

3,264

5,092

636

705

-522

1,353

1,445

338

-474

1,151

Accrued expenses and other liabilities

1,798

-1,129

1,330

-228

-1,556

2,168

374

-2,555

-909

505

4,214

1,181

-1,851

4,687

2,200

-2,632

4,726

-79

-1,653

385

2,985

859

-38

810

-170

Operating lease liabilities

-406

-428

-374

-338

806

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-7,865

-22,069

-15,853

-16,377

-11,209

-1,093

-22,720

-24,345

-20,601

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Investing Activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-22,842

-

-34,660

-2,527

-23,363

-2,944

-15,971

182,196

-8,471

25,121

-9,717

8,935

-4,974

Purchase of marketable securities

36,385

58,170

91,449

55,688

77,790

47,676

24,135

33,990

121,152

19,038

100,771

63,251

77,375

43,402

71,848

105,686

138,564

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

79,031

86,184

82,251

38,056

76,103

54,370

58,140

70,425

85,749

41,132

79,720

118,580

115,098

45,058

73,156

102,599

130,509

-

-

-

-

-

-

-

-

Purchase of property and equipment

48

77

801

-42

424

358

1,182

-1,294

2,119

1,772

1,929

712

741

4,408

8,943

9,171

1,365

358

651

851

314

304

211

141

126

Net cash provided by (used in) investing activities

42,598

27,937

-9,999

-17,590

-2,111

6,367

32,829

37,733

-37,522

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Flows from Financing Activities
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

36,982

-

-8,103

-12,258

-9,420

-28,659

-268,164

-851

-314

-304

-211

-141

-126

Proceeds from issuance of common stock, net of offering costs

-

-

-

-

-

-

-

-

-

1,835

16,689

42,666

17,801

-

-

-

-

-

-

-

-

-

-

-

-

Excess tax benefit from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-477

2,736

24

2,161

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

297

-

-

-

-

Proceeds from issuance of convertible promissory note payable to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

308

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

22,522

-

-

-

-

Proceeds from exercise of stock options

80

-2

93

188

251

129

68

643

617

371

1,429

240

195

426

223

52

299

496

3

214

88

-

-

-

-

Net cash provided by financing activities

80

47

93

352

251

292

-3,413

1,009

617

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes

-56

104

-197

62

-127

-7

-346

-275

171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

17,996

-

34,808

590

2,460

1,068

-741

151,538

22,313

55,088

10,040

26,905

308

Net increase (decrease) in cash, cash equivalents and restricted cash

34,757

6,019

-25,956

-33,553

-13,196

5,559

6,350

14,122

-57,335

-1,426

-24,775

76,747

32,136

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Accrued offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-168

910

-

-

-

-

Purchase of property and equipment in accounts payable and accrued liabilities

-

-

-

-

41

-32

-289

-129

781

1,894

677

69

150

-3,220

-468

2,976

1,159

613

-44

-91

214

-

-

-

-

Reconciliation of Cash, Cash Equivalents and Restricted Cash
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,955

-14,195

-30,323

-30,535

-284,876

332,883

13,528

79,905

112

35,699

-4,792